You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,485,769


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,485,769
Title:Transgenic mammals
Abstract: This invention provides a nonhuman transgenic mammal carrying transgene comprising the regulatory genes capable of functioning in the hyperacute rejection-occurring local cells and gene encoding human N-acetylglucosaminyltransferase III (GnT-III), or a nonhuman transgenic mammal carrying transgene comprising the regulatory genes and genes encoding GnT-III and the human complement inhibitor. Because of reduced .alpha.-Gal antigens in the hyperacute rejection-occurring local cells or because of both reduced .alpha.-Gal antigens and expression of the human complement inhibitor, the transgenic mammal of this invention can effectively inhibit the hyperacute rejection caused by discordant xenotransplantation. Consequently, this invention provides the transgenic mammal suitable for organ transplantation.
Inventor(s): Murakami; Hiroshi (Tsukuba, JP), Fujimura; Tatsuya (Tsukuba, JP), Takahagi; Yoichi (Tsukuba, JP), Toyomura; Koji (Tsukuba, JP), Shigehisa; Tamotsu (Tsukuba, JP)
Assignee: Nippon Meat Packers, Inc. (Osaka-shi, JP)
Application Number:10/362,429
Patent Claims:1. A transgenic pig, whose genome comprises a transgene encoding human N-acetylglucosaminyltransferase (GnT III), for providing organs for xenotransplantation comprising: regulatory sequences capable of functioning in the hyperacute rejection-occurring local cells, wherein said regulatory sequences are: (A) a promoter of porcine complement inhibitor and the first intron of a human CD55 gene, or (B) a cytomegalovirus (CMV) enhancer and chicken beta-actin promoter, and said transgene encoding human N-acetylglucosaminyltransferase III (GnT III), wherein said regulatory sequences are operably linked to said transgene encoding human GnT III, and wherein said transgenic pig expresses GnT III in one or more organs selected from the group consisting of: heart, liver, lung, kidney and spleen, and wherein expression of GnT III decreases expression of galactose-.alpha.-1,3-galactose antigen in the one or more organs selected from the group consisting of: heart, liver, lung, kidney and spleen, thereby decreasing hyperacute rejection in a human after xenotransplantation of said one or more organs into a human.

2. A method of producing a transgenic pig according to claim 1, which comprises: introducing said transgene encoding human GnT III into a pig pronuclei of a pre-nuclear phase pig egg by microinjection to produce a transgenic pig wherein said transgene encoding GnT III is operably linked to: (A) a promoter of porcine complement inhibitor and the first intron of a human CD55 gene, or (B) a cytomegalovirus (CMV) enhancer and chicken beta-actin promoter, thereby producing a transgenic pig whose genome comprises the transgene encoding human GnT III.

3. A transgenic pig, whose genome comprises a first transgene encoding human N-acetylglucosaminyltransferase III (GnT III) and whose genome comprises a second transgene encoding human complement inhibitor CD55, for providing organs for xenotransplantation comprising: said first transgene encoding human N-acetylglucosaminyltransferase III (GnT III) operably linked to a cytomegalovirus (CMV) enhancer and a chicken beta-actin promoter, and said second transgene encoding human complement inhibitor CD55 operably linked to a promoter of porcine complement inhibitor, wherein said transgenic pig expresses GnT III in one or more organs selected from the group consisting of: heart, liver, lung, kidney and spleen, and wherein expression of GnT III decreases expression of galactose-.alpha.-1,3-galactose antigen in the one or more organs selected from the group consisting of: heart, liver, lung, kidney and spleen, thereby decreasing hyperacute rejection in a human after xenotransplantation of said one or more organs into a human.

4. A method of producing a transgenic pig according to claim 3, which comprises: producing separately a first transgenic pig expressing human GnT III and a second transgenic pig expressing the human complement inhibitor CD55 by introducing said first transgene encoding human GnT III into a pig pronuclei of a first pre-nuclear phase pig egg by microinjection to produce a first transgenic pig, and introducing said second transgene encoding human complement inhibitor CD55 into a pig pronuclei of a second pre-nuclear phase pig egg by microinjection to produce a second transgenic pig, and breeding the first and second transgenic pigs to produce transgenic offspring, wherein said transgenic offspring express both human GnT III and human complement inhibitor CD55, and wherein said first transgene encoding GnT III is operably linked to a cytomegalovirus (CMV) enhancer and chicken beta-actin promoter, and wherein said second transgene encoding a human complement inhibitor CD55 is operably linked to a promoter of porcine complement inhibitor.

Details for Patent 7,485,769

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2020-08-25
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2020-08-25
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2020-08-25
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.